Our Biotech Trade Set to Profit as China Moves to the Head of the Line
The U.S. FDA isn’t alone in breaking records this year. China’s FDA has been making big strides as well. It just approved a new drug, a drug that belongs to one of Ray’s great recommendations…
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication(s) below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.